Title: DELIVERY OF SEDATIVE-HYPNOTICS THROUGH AN INHALATION ROUTE

Abstract: The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. In a method aspect of the present invention, a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of a sedative-hypnotic; and, b) a device that forms a sedative-hypnotic containing aerosol from the composition, for inhalation by the mammal.
DELIVERY OF SEDATIVE-HYPNOTICS THROUGH AN INHALATION ROUTE

[0001] This application claims priority to U.S. provisional application Ser. No. 60/294,203 entitled "Thermal Vapor Delivery of Drugs," filed May 24, 2001, Rabinowitz and Zaffaroni, the entire disclosure of which is hereby incorporated by reference. This application further claims priority to U.S. provisional application Ser. No. 60/317,479 entitled "Aerosol Drug Delivery," filed September 5, 2001, Rabinowitz and Zaffaroni, the entire disclosure of which is hereby incorporated by reference.

Field of the Invention

[0002] The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy.

Background of the Invention

[0003] There are a number of compositions currently marketed as sedative-hypnotics. The compositions contain at least one active ingredient that provides for observed therapeutic effects. Among the active ingredients given in sedative-hypnotic compositions are zolpidem, zaleplon, and zopiclone.

It is desirable to provide a new route of administration for sedative-hypnotics that rapidly produces peak plasma concentrations of the compound. The provision of such a route is an object of the present invention.

Summary of the Invention

[0004] The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy.

[0005] In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. Preferably, the particles comprise at least 10 percent by weight of a sedative hypnotic. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent or 99.97 percent by weight of a sedative hypnotic.
[0006] Typically, the aerosol has a mass of at least 10 μg. Preferably, the aerosol has a mass of at least 100 μg. More preferably, the aerosol has a mass of at least 200 μg.

[0007] Typically, the particles comprise less than 10 percent by weight of sedative-hypnotic degradation products. Preferably, the particles comprise less than 5 percent by weight of sedative-hypnotic degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of sedative-hypnotic degradation products.

[0008] Typically, the particles comprise less than 90 percent by weight of water. Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent, 30 percent, 20 percent, 10 percent, or 5 percent by weight of water.

[0009] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.

[0010] Typically, the aerosol has an inhalable aerosol particle density greater than $10^6$ particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than $10^7$ particles/mL or $10^8$ particles/mL.

[0011] Typically, the aerosol particles have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).

[0012] Typically, the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 3.0. Preferably, the geometric standard deviation is less than 2.5. More preferably, the geometric standard deviation is less than 2.2.

[0013] Typically, the aerosol is formed by heating a composition containing a sedative-hypnotic to form a vapor and subsequently allowing the vapor to condense into an aerosol.

[0014] In another composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of zaleplon, zolpidem or zopiclone. Preferably, the particles comprise at least 10 percent by weight of zaleplon, zolpidem or
zopiclone. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent or 99.97 percent by weight of zaleplon, zolpidem or zopiclone.

[0015] Typically, the aerosol has a mass of at least 10 μg. Preferably, the aerosol has a mass of at least 100 μg. More preferably, the aerosol has a mass of at least 200 μg.

[0016] Typically, the particles comprise less than 10 percent by weight of zaleplon, zolpidem or zopiclone degradation products. Preferably, the particles comprise less than 5 percent by weight of zaleplon, zolpidem or zopiclone degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of zaleplon, zolpidem or zopiclone degradation products.

[0017] Typically, the particles comprise less than 90 percent by weight of water. Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent, 30 percent, 20 percent, 10 percent, or 5 percent by weight of water.

[0018] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.

[0019] Typically, the aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 40 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 20 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 10 mg/L.

[0020] Typically, the aerosol has an inhalable aerosol particle density greater than 10⁶ particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 10⁷ particles/mL or 10⁸ particles/mL.

[0021] Typically, the aerosol particles have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).

[0022] Typically, the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 3.0. Preferably, the geometric
standard deviation is less than 2.5. More preferably, the geometric standard deviation is less than 2.2.

[0023] Typically, the aerosol is formed by heating a composition containing zaleplon, zolpidem or zopiclone to form a vapor and subsequently allowing the vapor to condense into an aerosol.

[0024] In a method aspect of the present invention, one of a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. Preferably, the composition that is heated comprises at least 10 percent by weight of a sedative-hypnotic. More preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of a sedative-hypnotic.

[0025] Typically, the particles comprise at least 5 percent by weight of a sedative-hypnotic. Preferably, the particles comprise at least 10 percent by weight of a sedative-hypnotic. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of a sedative-hypnotic.

[0026] Typically, the condensation aerosol has a mass of at least 10 μg. Preferably, the aerosol has a mass of at least 100 μg. More preferably, the aerosol has a mass of at least 200 μg.

[0027] Typically, the particles comprise less than 10 percent by weight of sedative-hypnotic degradation products. Preferably, the particles comprise less than 5 percent by weight of sedative-hypnotic degradation products. More preferably, the particles comprise 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of sedative-hypnotic degradation products.

[0028] Typically, the particles comprise less than 90 percent by weight of water. Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent, 30 percent, 20 percent, 10 percent, or 5 percent by weight of water.

[0029] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol.
weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.

[0030] Typically, the particles of the delivered condensation aerosol have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).

[0031] Typically, the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 3.0. Preferably, the geometric standard deviation is less than 2.5. More preferably, the geometric standard deviation is less than 2.2.

[0032] Typically, the delivered aerosol has an inhalable aerosol particle density greater than $10^6$ particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than $10^7$ particles/mL or $10^8$ particles/mL.

[0033] Typically, the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than $10^8$ particles per second. Preferably, the aerosol is formed at a rate greater than $10^9$ inhaleable particles per second. More preferably, the aerosol is formed at a rate greater than $10^{10}$ inhaleable particles per second.

[0034] Typically, the delivered condensation aerosol is formed at a rate greater than 0.5 mg/second. Preferably, the aerosol is formed at a rate greater than 0.75 mg/second. More preferably, the aerosol is formed at a rate greater than 1 mg/second, 1.5 mg/second or 2 mg/second.

[0035] Typically, the delivered condensation aerosol results in a peak plasma concentration of a sedative-hypnotic in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02, 0.01, or 0.005 h (arterial measurement).

[0036] Typically, the delivered condensation aerosol is used to treat insomnia.

[0037] In another method aspect of the present invention, one of zaleplon, zolpidem or zopiclone is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of zaleplon, zolpidem or zopiclone, to form a vapor; and, b) allowing the vapor to cool,
thereby forming a condensation aerosol comprising particles, which is inhaled by the
mammal. Preferably, the composition that is heated comprises at least 10 percent by
weight of zaleplon, zolpidem or zopiclone. More preferably, the composition comprises at
least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90
percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by
weight of zaleplon, zolpidem or zopiclone.

[0038] Typically, the particles comprise at least 5 percent by weight of zaleplon,
zolpidem or zopiclone. Preferably, the particles comprise at least 10 percent by weight of
zaleplon, zolpidem or zopiclone. More preferably, the particles comprise at least 20
percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent,
95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of
zaleplon, zolpidem or zopiclone.

[0039] Typically, the condensation aerosol has a mass of at least 10 µg. Preferably, the
aerosol has a mass of at least 100 µg. More preferably, the aerosol has a mass of at least
200 µg.

[0040] Typically, the particles comprise less than 10 percent by weight of zaleplon,
zolpidem or zopiclone degradation products. Preferably, the particles comprise less than 5
percent by weight of zaleplon, zolpidem or zopiclone degradation products. More
preferably, the particles comprise 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of zaleplon,
zolpidem or zopiclone degradation products.

[0041] Typically, the particles comprise less than 90 percent by weight of water.
Preferably, the particles comprise less than 80 percent by weight of water. More
preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent,
30 percent, 20 percent, 10 percent, or 5 percent by weight of water.

[0042] Typically, at least 50 percent by weight of the aerosol is amorphous in form,
wherein crystalline forms make up less than 50 percent by weight of the total aerosol
weight, regardless of the nature of individual particles. Preferably, at least 75 percent by
weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight
of the aerosol is amorphous in form.

[0043] Typically, the particles of the delivered condensation aerosol have a mass
median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass
median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).

**[0044]** Typically, the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 3.0. Preferably, the geometric standard deviation is less than 2.5. More preferably, the geometric standard deviation is less than 2.2.

**[0045]** Typically, the delivered aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 40 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 20 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 10 mg/L.

**[0046]** More preferably, the aerosol has an inhalable aerosol drug mass density of between 1.5 mg/L and 7.5 mg/L.

**[0047]** Typically, the delivered aerosol has an inhalable aerosol particle density greater than \(10^6\) particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than \(10^7\) particles/mL or \(10^8\) particles/mL.

**[0048]** Typically, the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than \(10^8\) particles per second. Preferably, the aerosol is formed at a rate greater than \(10^9\) inhalable particles per second. More preferably, the aerosol is formed at a rate greater than \(10^{10}\) inhalable particles per second.

**[0049]** Typically, the delivered condensation aerosol is formed at a rate greater than 0.5 mg/second. Preferably, the aerosol is formed at a rate greater than 0.75 mg/second. More preferably, the aerosol is formed at a rate greater than 1 mg/second, 1.5 mg/second or 2 mg/second.

**[0050]** Typically, between 0.5 mg and 40 mg of drug are delivered to the mammal in a single inspiration. Preferably, between 1 mg and 20 mg of drug are delivered to the mammal in a single inspiration. More preferably, between 1 mg and 10 mg of drug are delivered to the mammal in a single inspiration.

**[0051]** Typically, the delivered condensation aerosol results in a peak plasma concentration of zaleplon, zolpidem or zopiclone in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02, 0.01, or 0.005 h (arterial measurement).
Typically, the delivered condensation aerosol is used to treat insomnia.

In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of a sedative-hypnotic; and, b) a device that forms a sedative-hypnotic aerosol from the composition, for inhalation by the mammal. Preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of a sedative-hypnotic.

Typically, the device contained in the kit comprises: a) an element for heating the sedative-hypnotic composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.

In another kit aspect of the present invention, a kit for delivering zaleplon, zolpidem or zopiclone through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of zaleplon, zolpidem or zopiclone; and, b) a device that forms a zaleplon, zolpidem or zopiclone aerosol from the composition, for inhalation by the mammal. Preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of zaleplon, zolpidem or zopiclone.

Typically, the device contained in the kit comprises: a) an element for heating the zaleplon, zolpidem or zopiclone composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.

**Brief Description of the Figure**

Fig. 1 shows a cross-sectional view of a device used to deliver sedative-hypnotic aerosols to a mammal through an inhalation route.

**Detailed Description of the Invention**

**Definitions**

“Aerodynamic diameter” of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
“Aerosol” refers to a suspension of solid or liquid particles in a gas.

“Aerosol drug mass density” refers to the mass of sedative-hypnotic per unit volume of aerosol.

“Aerosol mass density” refers to the mass of particulate matter per unit volume of aerosol.

“Aerosol particle density” refers to the number of particles per unit volume of aerosol.

“Amorphous particle” refers to a particle that does not contain more than 50 percent by weight of a crystalline form. Preferably, the particle does not contain more than 25 percent by weight of a crystalline form. More preferably, the particle does not contain more than 10 percent by weight of a crystalline form.

“Condensation aerosol” refers to an aerosol formed by vaporization of a substance followed by condensation of the substance into an aerosol.

“Inhalable aerosol drug mass density” refers to the aerosol drug mass density produced by an inhalation device and delivered into a typical patient tidal volume.

“Inhalable aerosol mass density” refers to the aerosol mass density produced by an inhalation device and delivered into a typical patient tidal volume.

“Inhalable aerosol particle density” refers to the aerosol particle density of particles of size between 100 nm and 5 microns produced by an inhalation device and delivered into a typical patient tidal volume.

“Mass median aerodynamic diameter” or “MMAD” of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.

“Rate of aerosol formation” refers to the mass of aerosolized particulate matter produced by an inhalation device per unit time.

“Rate of inhalable aerosol particle formation” refers to the number of particles of size between 100 nm and 5 microns produced by an inhalation device per unit time.

“Rate of drug aerosol formation” refers to the mass of aerosolized sedative-hypnotic produced by an inhalation device per unit time.

“Settling velocity” refers to the terminal velocity of an aerosol particle undergoing gravitational settling in air.
[0073] "Sedative-hypnotic degradation product" refers to a compound resulting from a chemical modification of a sedative-hypnotic. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.

[0074] "Typical patient tidal volume" refers to 1 L for an adult patient and 15 mL/kg for a pediatric patient.

[0075] "Vapor" refers to a gas, and "vapor phase" refers to a gas phase. The term "thermal vapor" refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating.

[0076] "Zaleplon" refers to N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide, which is a free base.

[0077] "Zaleplon" degradation product refers to a compound resulting from a chemical modification of zaleplon. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis. An example of a degradation product is C_{13}H_{9}N_{5} (de-ethylation and de-amidation to provide unsubstituted aniline moiety).

[0078] "Zolpidem" refers to N,N,6-trimethyl-2-p-tolyl-imidazo[1,2-a]pyridine-3-acetamide, which is a free base.

[0079] "Zolpidem" degradation product refers to a compound resulting from a chemical modification of zolpidem. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis. An example of a degradation product is C_{16}H_{14}N_{2}O (amide removal).

[0080] "Zopiclone" refers to 4-methyl-1-piperazinecarboxylic acid 6-[5-chloro-2-pyridinyl]-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester

[0081] "Zolpiclone" degradation product refers to a compound resulting from a chemical modification of zopiclone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis. Examples of degradation products include 2-amino-5-chloropyridine and 1-methyl piperazine.

Formation of Sedative-Hypnotic Containing Aerosols

[0082] Any suitable method is used to form the aerosols of the present invention. A preferred method, however, involves heating a composition comprising a sedative-hypnotic
to form a vapor, followed by cooling of the vapor such that it condenses to provide a sedative-hypnotic comprising aerosol (condensation aerosol). The composition is heated in one of four forms: as pure active compound (i.e., pure zaleplon, zolpidem or zopiclone); as a mixture of active compound and a pharmaceutically acceptable excipient; as a salt form of the pure active compound; and, as a mixture of active compound salt form and a pharmaceutically acceptable excipient.

Salt forms of sedative-hypnotics (e.g., zaleplon, zolpidem or zopiclone) are either commercially available or are obtained from the corresponding free base using well known methods in the art. A variety of pharmaceutically acceptable salts are suitable for aerosolization. Such salts include, without limitation, the following: hydrochloric acid, hydrobromic acid, acetic acid, maleic acid, formic acid, and fumaric acid salts.

Pharmacologically acceptable excipients may be volatile or nonvolatile. Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled with the sedative-hypnotic. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within the classes: water; terpenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof.

Solid supports on which the composition is heated are of a variety of shapes. Examples of such shapes include, without limitation, cylinders of less than 1.0 mm in diameter, boxes of less than 1.0 mm thickness and virtually any shape permeated by small (e.g., less than 1.0 mm-sized) pores. Preferably, solid supports provide a large surface to volume ratio (e.g., greater than 100 per meter) and a large surface to mass ratio (e.g., greater than 1 cm² per gram).

A solid support of one shape can also be transformed into another shape with different properties. For example, a flat sheet of 0.25 mm thickness has a surface to volume ratio of approximately 8,000 per meter. Rolling the sheet into a hollow cylinder of 1 cm diameter produces a support that retains the high surface to mass ratio of the original sheet but has a lower surface to volume ratio (about 400 per meter).

A number of different materials are used to construct the solid supports. Classes of such materials include, without limitation, metals, inorganic materials, carbonaceous materials and polymers. The following are examples of the material classes: aluminum,
silver, gold, stainless steel, copper and tungsten; silica, glass, silicon and alumina; graphite, porous carbons, carbon yarns and carbon felts; polytetrafluoroethylene and polyethylene glycol. Combinations of materials and coated variants of materials are used as well.

Where aluminum is used as a solid support, aluminum foil is a suitable material. Examples of silica, alumina and silicon based materials include amorphous silica S-5631 (Sigma, St. Louis, MO), BCR171 (an alumina of defined surface area greater than 2 m$^2$/g from Aldrich, St. Louis, MO) and a silicon wafer as used in the semiconductor industry. Carbon yarns and felts are available from American Kynol, Inc., New York, NY. Chromatography resins such as octadecylsilane chemically bonded to porous silica are exemplary coated variants of silica.

The heating of the sedative-hypnotic compositions is performed using any suitable method. Examples of methods by which heat can be generated include the following: passage of current through an electrical resistance element; absorption of electromagnetic radiation, such as microwave or laser light; and, exothermic chemical reactions, such as exothermic solvation, hydration of pyrophoric materials and oxidation of combustible materials.

**Delivery of Sedative-Hypnotic Containing Aerosols**

Sedative-hypnotic containing aerosols of the present invention are delivered to a mammal using an inhalation device. Where the aerosol is a condensation aerosol, the device has at least three elements: an element for heating a sedative-hypnotic containing composition to form a vapor; an element allowing the vapor to cool, thereby providing a condensation aerosol; and, an element permitting the mammal to inhale the aerosol. Various suitable heating methods are described above. The element that allows cooling is, in its simplest form, an inert passageway linking the heating means to the inhalation means. The element permitting inhalation is an aerosol exit portal that forms a connection between the cooling element and the mammal’s respiratory system.

One device used to deliver the sedative-hypnotic containing aerosol is described in reference to Fig. 1. Delivery device 100 has a proximal end 102 and a distal end 104, a heating module 106, a power source 108, and a mouthpiece 110. A sedative-hypnotic composition is deposited on a surface 112 of heating module 106. Upon activation of a user activated switch 114, power source 108 initiates heating of heating module 106 (e.g., through ignition of combustible fuel or passage of current through a resistive heating
element). The sedative-hypnotic composition volatilizes due to the heating of heating module 106 and condenses to form a condensation aerosol prior to reaching the mouthpiece 110 at the proximal end of the device 102. Air flow traveling from the device distal end 104 to the mouthpiece 110 carries the condensation aerosol to the mouthpiece 110, where it is inhaled by the mammal.

[0092] Devices, if desired, contain a variety of components to facilitate the delivery of sedative-hypnotic containing aerosols. For instance, the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation (e.g., breath-actuation), to provide feedback to patients on the rate and/or volume of inhalation, to prevent excessive use (i.e., "lock-out" feature), to prevent use by unauthorized individuals, and/or to record dosing histories.

**Dosage of Sedative-Hypnotic Containing Aerosols**

[0093] The dosage amount of sedative-hypnotics in aerosol form is generally no greater than twice the standard dose of the drug given orally. For instance, zaleplon, zolpidem and zopiclone are given orally at strengths of 5 mg or 10 mg for the treatment of insomnia. As aerosols, 0.5 mg to 40 mg of the compounds are generally provided per inspiration for the same indication. A typical dosage of a sedative-hypnotic aerosol is either administered as a single inhalation or as a series of inhalations taken within an hour or less (dosage equals sum of inhaled amounts). Where the drug is administered as a series of inhalations, a different amount may be delivered in each inhalation.

[0094] One can determine the appropriate dose of sedative-hypnotic containing aerosols to treat a particular condition using methods such as animal experiments and a dose-finding (Phase I/II) clinical trial. One animal experiment involves measuring plasma concentrations of drug in an animal after its exposure to the aerosol. Mammals such as dogs or primates are typically used in such studies, since their respiratory systems are similar to that of a human. Initial dose levels for testing in humans is generally less than or equal to the dose in the mammal model that resulted in plasma drug levels associated with a therapeutic effect in humans. Dose escalation in humans is then performed, until either an optimal therapeutically response is obtained or a dose-limiting toxicity is encountered.

**Analysis of Sedative-Hypnotic Containing Aerosols**

[0095] Purity of a sedative-hypnotic containing aerosol is determined using a number of methods, examples of which are described in Sekine et al., *Journal of Forensic Science*
32:1271-1280 (1987) and Martin et al., Journal of Analytic Toxicology 13:158-162 (1989). One method involves forming the aerosol in a device through which a gas flow (e.g., air flow) is maintained, generally at a rate between 0.4 and 60 L/min. The gas flow carries the aerosol into one or more traps. After isolation from the trap, the aerosol is subjected to an analytical technique, such as gas or liquid chromatography, that permits a determination of composition purity.

[0096] A variety of different traps are used for aerosol collection. The following list contains examples of such traps: filters; glass wool; impingers; solvent traps, such as dry ice-cooled ethanol, methanol, acetone and dichloromethane traps at various pH values; syringes that sample the aerosol; empty, low-pressure (e.g., vacuum) containers into which the aerosol is drawn; and, empty containers that fully surround and enclose the aerosol generating device. Where a solid such as glass wool is used, it is typically extracted with a solvent such as ethanol. The solvent extract is subjected to analysis rather than the solid (i.e., glass wool) itself. Where a syringe or container is used, the container is similarly extracted with a solvent.

[0097] The gas or liquid chromatograph discussed above contains a detection system (i.e., detector). Such detection systems are well known in the art and include, for example, flame ionization, photon absorption and mass spectrometry detectors. An advantage of a mass spectrometry detector is that it can be used to determine the structure of sedative-hypnotic degradation products.

[0098] Particle size distribution of a sedative-hypnotic containing aerosol is determined using any suitable method in the art (e.g., cascade impaction). An Andersen Eight Stage Non-viable Cascade Impactor (Andersen Instruments, Smyrna, GA) linked to a furnace tube by a mock throat (USP throat, Andersen Instruments, Smyrna, GA) is one system used for cascade impaction studies.

[0099] Inhalable aerosol mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the mass collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient.
Inhalable aerosol drug mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the amount of active drug compound collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient. The amount of active drug compound collected in the chamber is determined by extracting the chamber, conducting chromatographic analysis of the extract and comparing the results of the chromatographic analysis to those of a standard containing known amounts of drug.

Inhalable aerosol particle density is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device and measuring the number of particles of given size collected in the chamber. The number of particles of a given size may be directly measured based on the light-scattering properties of the particles. Alternatively, the number of particles of a given size is determined by measuring the mass of particles within the given size range and calculating the number of particles based on the mass as follows: Total number of particles = Sum (from size range 1 to size range N) of number of particles in each size range. Number of particles in a given size range = Mass in the size range/Mass of a typical particle in the size range. Mass of a typical particle in a given size range = \( \pi \cdot D^3 \cdot \varphi / 6 \), where D is a typical particle diameter in the size range (generally, the mean boundary MMADs defining the size range) in microns, \( \varphi \) is the particle density (in g/mL) and mass is given in units of picograms (g \( \cdot \) 12).

Rate of inhalable aerosol particle formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time (e.g., 3 s), and the number of particles of a given size collected in the chamber is determined as outlined above. The rate of particle formation is equal to the number of 100 nm to 5 micron particles collected divided by the duration of the collection time.

Rate of aerosol formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time (e.g., 3 s), and the mass of particulate matter collected is determined by weighing the confined chamber before and after the delivery of the particulate matter. The rate of aerosol formation is equal to the increase in mass in the chamber divided by the
duration of the collection time. Alternatively, where a change in mass of the delivery
device or component thereof can only occur through release of the aerosol phase particulate
matter, the mass of particulate matter may be equated with the mass lost from the device or
component during the delivery of the aerosol. In this case, the rate of aerosol formation is
equal to the decrease in mass of the device or component during the delivery event divided
by the duration of the delivery event.

[0104] Rate of drug aerosol formation is determined, for example, by delivering a
sedative-hypnotic containing aerosol into a confined chamber via an inhalation device over
a set period of time (e.g., 3 s). Where the aerosol is pure sedative-hypnotic, the amount of
drug collected in the chamber is measured as described above. The rate of drug aerosol
formation is equal to the amount of sedative-hypnotic collected in the chamber divided by
the duration of the collection time. Where the sedative-hypnotic containing aerosol
comprises a pharmaceutically acceptable excipient, multiplying the rate of aerosol
formation by the percentage of sedative-hypnotic in the aerosol provides the rate of drug
aerosol formation.

Utility of Sedative-Hypnotic Containing Aerosols

[0105] The sedative-hypnotic containing aerosols of the present invention are typically
used for the treatment of insomnia. Other uses for the aerosols include, without limitation,
the following: an anticonvulsant; an anxiolytic; and, a myorelaxant.

[0106] The following examples are meant to illustrate, rather than limit, the present
invention.

[0107] Zolpidem and zopiclone are commercially available from Sigma (www.sigma-
aldrich.com). Zaleplon is available in capsule form (SONATA®) and can be isolated using
standard methods in the art.

EXAMPLE 1

Volatileization of Zaleplon

[0108] A solution of 5.5 mg zaleplon in approximately 120 μL dichloromethane was
coated on a 3 cm x 8 cm piece of aluminum foil. The dichloromethane was allowed to
evaporate. The coated foil was wrapped around a 300 watt halogen tube (Feit Electric
Company, Pico Rivera, CA), which was inserted into a glass tube sealed at one end with a
rubber stopper. Running 60 V of alternating current (driven by line power controlled by a
variac) through the bulb for 7 s afforded zaleplon thermal vapor (including zaleplon
aerosol), which collected on the glass tube walls. Reverse-phase HPLC analysis with
detection by absorption of 225 nm light showed the collected material to be greater than
99% pure zaleplon.

EXAMPLE 2

Volatilization of Zolpidem

[0109] A solution of 5.3 mg zolpidem in approximately 120 µL dichloromethane was
coated on a 3 cm x 8 cm piece of aluminum foil. The dichloromethane was allowed to
evaporate. The coated foil was wrapped around a 300 watt halogen tube (Feit Electric
Company, Pico Rivera, CA), which was inserted into a glass tube sealed at one end with a
rubber stopper. Running 60 V of alternating current (driven by line power controlled by a
variac) through the bulb for 6 s afforded zolpidem thermal vapor (including zolpidem
aerosol), which collected on the glass tube walls. Reverse-phase HPLC analysis with
detection by absorption of 225 nm light showed the collected material to be greater than
99% pure zolpidem.

EXAMPLE 3

Volatilization of Zopiclone

[0110] A solution of 3.5 mg zopiclone in approximately 120 µL dichloromethane was
coated on a 3 cm x 8 cm piece of aluminum foil. The dichloromethane was allowed to
evaporate. The coated foil was wrapped around a 300 watt halogen tube (Feit Electric
Company, Pico Rivera, CA), which was inserted into a glass tube sealed at one end with a
rubber stopper. Running 60 V of alternating current (driven by line power controlled by a
variac) through the bulb for 6 s afforded zopiclone thermal vapor (including zopiclone
aerosol), which collected on the glass tube walls. Reverse-phase HPLC analysis with
detection by absorption of 225 nm light showed the collected material to be greater than
99% pure zopiclone.

EXAMPLE 4

Particle Size, Particle Density, and
Rate of Inhalable Particle Formation of Zolpidem Aerosol

[0111] A solution of 10.7 mg zolpidem in 100 µL dichloromethane was spread out in a
thin layer on the central portion of a 3.5 cm x 7 cm sheet of aluminum foil. The
dichloromethane was allowed to evaporate. The aluminum foil was wrapped around a 300
watt halogen tube, which was inserted into a T-shaped glass tube. Both of the openings of
the tube were sealed with parafilm, which was punctured with fifteen needles for air flow. The third opening was connected to a 1 liter, 3-neck glass flask. The glass flask was further connected to a large piston capable of drawing 1.1 liters of air through the flask. Alternating current was run through the halogen bulb by application of 90 V using a variac connected to 110 V line power. Within 1 s, an aerosol appeared and was drawn into the 1 L flask by use of the piston, with collection of the aerosol terminated after 6 s. The aerosol was analyzed by connecting the 1 L flask to an eight-stage Andersen non-viable cascade impactor. Results are shown in table 1. MMAD of the collected aerosol was 2.9 microns with a geometric standard deviation of 2.1. Also shown in table 1 is the number of particles collected on the various stages of the cascade impactor, given by the mass collected on the stage divided by the mass of a typical particle trapped on that stage. The mass of a single particle of diameter D is given by the volume of the particle, \( \pi D^3/6 \), multiplied by the density of the drug (taken to be 1 g/cm\(^3\)). The inhalable aerosol particle density is the sum of the numbers of particles collected on impactor stages 3 to 8 divided by the collection volume of 1 L, giving an inhalable aerosol particle density of 3.9 \times 10^6 particles/mL. The rate of inhalable aerosol particle formation is the sum of the numbers of particles collected on impactor stages 3 through 8 divided by the formation time of 6 s, giving a rate of inhalable aerosol particle formation of 6.4 \times 10^8 particles/second.

Table 1: Determination of the characteristics of a zolpidem condensation aerosol by cascade impaction using an Andersen 8-stage non-viable cascade impactor run at 1 cubic foot per minute air flow.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Particle size range (microns)</th>
<th>Average particle size (microns)</th>
<th>Mass collected (mg)</th>
<th>Number of particles</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>9.0-10.0</td>
<td>9.5</td>
<td>0.1</td>
<td>2.2 \times 10^5</td>
</tr>
<tr>
<td>1</td>
<td>5.8-9.0</td>
<td>7.4</td>
<td>0.3</td>
<td>1.4 \times 10^6</td>
</tr>
<tr>
<td>2</td>
<td>4.7-5.8</td>
<td>5.25</td>
<td>0.4</td>
<td>5.3 \times 10^6</td>
</tr>
<tr>
<td>3</td>
<td>3.3-4.7</td>
<td>4.0</td>
<td>0.9</td>
<td>2.7 \times 10^7</td>
</tr>
<tr>
<td>4</td>
<td>2.1-3.3</td>
<td>2.7</td>
<td>1.1</td>
<td>1.1 \times 10^8</td>
</tr>
<tr>
<td>5</td>
<td>1.1-2.1</td>
<td>1.6</td>
<td>0.8</td>
<td>3.7 \times 10^8</td>
</tr>
<tr>
<td>6</td>
<td>0.7-1.1</td>
<td>0.9</td>
<td>0.4</td>
<td>1.1 \times 10^9</td>
</tr>
<tr>
<td>7</td>
<td>0.4-0.7</td>
<td>0.55</td>
<td>0.2</td>
<td>2.3 \times 10^9</td>
</tr>
<tr>
<td>8</td>
<td>0-0.4</td>
<td>0.2</td>
<td>0.0</td>
<td>0</td>
</tr>
</tbody>
</table>

EXAMPLE 5
Drug Mass Density and Rate of Drug Aerosol Formation of Zolpidem Aerosol

A solution of 8.3 mg zolpidem in 100 μL dichloromethane was spread out in a thin layer on the central portion of a 3.5 cm x 7 cm sheet of aluminum foil. The dichloromethane was allowed to evaporate. The aluminum foil was wrapped around a 300 watt halogen tube, which was inserted into a T-shaped glass tube. Both of the openings of the tube were sealed with parafilm, which was punctured with fifteen needles for air flow. The third opening was connected to a 1 liter, 3-neck glass flask. The glass flask was further connected to a large piston capable of drawing 1.1 liters of air through the flask. Alternating current was run through the halogen bulb by application of 90 V using a variac connected to 110 V line power. Within seconds, an aerosol appeared and was drawn into the 1 L flask by use of the piston, with formation of the aerosol terminated after 6 s. The aerosol was allowed to sediment onto the walls of the 1 L flask for approximately 30 minutes. The flask was then extracted with acetonitrile and the extract analyzed by HPLC with detection by light absorption at 225 nm. Comparison with standards containing known amounts of zolpidem revealed that 3.7 mg of > 97% pure zolpidem had been collected in the flask, resulting in an aerosol drug mass density of 3.7 mg/L. The aluminum foil upon which the zolpidem had previously been coated was weighed following the experiment. Of the 8.3 mg originally coated on the aluminum, 7.4 mg of the material was found to have aerosolized in the 6 s time period, implying a rate of drug aerosol formation of 1.2 mg/s.
CLAIMS

1. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of a sedative-hypnotic.

2. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of zaleplon, zolpidem or zopiclone.

3. The aerosol according to Claim 2, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.

4. The aerosol according to Claim 2, wherein the particles comprise less than 2.5 percent by weight of zaleplon, zolpidem or zopiclone degradation products.

5. The aerosol according to Claim 3, wherein the aerosol comprises particles comprising at least 90 percent by weight of zaleplon, zolpidem or zopiclone.

6. The aerosol according to Claim 5, wherein the aerosol comprises particles comprising at least 97 percent by weight of zaleplon, zolpidem or zopiclone.

7. A method of delivering zaleplon, zolpidem or zopiclone to a mammal through an inhalation route, wherein the route comprises:
   a) heating a composition, wherein the composition comprises at least 5 percent by weight of zaleplon, zolpidem or zopiclone, to form a vapor; and,
   b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles,
      which is inhaled by the mammal.

8. The method according to Claim 7, wherein the particles comprise at least 10 percent by weight of zaleplon, zolpidem or zopiclone.

9. The method according to Claim 7, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.
10. The method according to Claim 7, wherein the particles comprise less than 2.5 percent by weight of zaleplon, zolpidem or zopiclone degradation products.

11. The method according to Claim 9, wherein the aerosol comprises particles comprising at least 90 percent by weight of zaleplon, zolpidem or zopiclone.

12. The method according to Claim 11, wherein the aerosol comprises particles comprising at least 97 percent by weight of zaleplon, zolpidem or zopiclone.

13. A kit for delivering zaleplon, zolpidem or zopiclone through an inhalation route to a mammal, wherein the kit comprises:
   a) a composition comprising at least 5 percent by weight of zaleplon, zolpidem or zopiclone; and,
   b) a device that forms a zaleplon, zolpidem or zopiclone aerosol from the composition, for inhalation by the mammal and wherein the device comprises:
      a) an element for heating the zaleplon, zolpidem or zopiclone composition to form a vapor;
      b) an element allowing the vapor to cool to form an aerosol; and,
      c) an element permitting the mammal to inhale the aerosol.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/72 A61K31/437 A61K31/519 A61K31/4985

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEMABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P,X</td>
<td>WO 02 24158 A (ADVANCED INHALATION RES INC ; BARTUS RAYMOND T (US); EMERICH DWAINÉ) 28 March 2002 (2002-03-28) page 5, line 11 - page 6, line 27 page 7, line 9 - line 23 page 12, line 1 - page 13, line 29 page 22, line 1 - page 23, line 16 page 30, line 26 - page 32, line 1</td>
<td>1-6</td>
</tr>
<tr>
<td>P,A</td>
<td>----</td>
<td>7-13</td>
</tr>
<tr>
<td>A</td>
<td>US 5 388 574 A (INGEBRETHSEN BRADLEY J) 14 February 1995 (1995-02-14) the whole document</td>
<td>1-13</td>
</tr>
</tbody>
</table>

[Special categories of cited documents:

* Document defining the general state of the art which is not considered to be of particular relevance
* Earlier document but published on or after the international filing date
* Document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* Document referring to an oral disclosure, use, exhibition or other means
* Document published prior to the international filing date but later than the priority date claimed

X Patent family members are listed in annex.

T Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X Document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

V Document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A Document member of the same patent family]

Date of the actual completion of the international search

10 October 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fac (+31-70) 340-3016

Date of mailing of the international search report

18/10/2002

Authorized officer

Giménez Miralles, J

Form PCT/ISA/210 (second sheet) [July 1992]
Continuation of Box I.1

Although claims 7-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 7-12

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
### Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 7–12 because they relate to subject matter not required to be searched by this Authority, namely:
   
   see FURTHER INFORMATION sheet PCT/ISA/210

2. **☐** Claims Nos.:  
   because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. **☐** Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. **☐** As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. **☐** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. **☐** As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. **☐** No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- **☐** The additional search fees were accompanied by the applicant's protest.
- **☐** No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU 9112201 A</td>
<td>02-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0224158 A2</td>
<td>28-03-2002</td>
</tr>
<tr>
<td>US 5388574 A</td>
<td>14-02-1995</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>